Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 477 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: System Lupus Erythematosus(SLE) Clear all
Completed No phase listed Observational

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

NCT00582881
View directory record Official record
Conditions
Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 24, 2026, 4:53 AM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

NCT04907175
View directory record Official record
Conditions
System; Lupus Erythematosus
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years · Female only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 24, 2026, 4:53 AM EDT
Completed No phase listed Observational

Insulin Resistance and Atherosclerosis in Women With Lupus

NCT00544102
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
30 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 24, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

NCT03616964
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jul 24, 2026, 4:53 AM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

NCT02106897
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy Volunteers
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

NCT02472795
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Matching placebo, Cenerimod
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Anniston, Alabama • Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 24, 2026, 4:53 AM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

NCT01408576
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Triptorelin Pamoate, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 24, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional

Study of LJP 394 in Lupus Patients With History of Renal Disease

NCT00089804
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
12 Years to 70 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Leandro, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Jul 24, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus

NCT02456168
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 24, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00111306
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Jul 24, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
13
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 24, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
M5049 low dose, M5049 medium dose, M5049 high dose, Placebo
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 76 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Activity and Nutrition Trial in Lupus to Energize and Renew

NCT02281513
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Physical Activity, Sleep
Interventions
Smartphone Application, Fitbit Activity Monitor, Coaching Sessions
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 24, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

NCT06445127
View directory record Official record
Conditions
SLE (Systemic Lupus)
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 24, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

NCT06977724
View directory record Official record
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Margate, Florida • Tampa, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
Interventions
Hydroxychloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262727
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Jul 24, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

NCT06041568
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Erythematosus
Interventions
Imvotamab
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
San Diego, California • San Leandro, California • DeBary, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 24, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

NCT00519363
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
atorvastatin
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jul 24, 2026, 4:53 AM EDT